The Technical Analyst
First Trust Nasdaq [FTXH]
Exchange: NASDAQ
First Trust Nasdaq Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.15% $25.78
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 20.93 mill |
| EPS: | 1.677 |
| P/E: | 15.37 |
| Earnings Date: | N/A |
| SharesOutstanding: | 0.812 mill |
| Avg Daily Volume: | 0.0058 mill |
| PE RATIO: COMPANY / SECTOR |
|---|
| 1.05x |
| Company: PE 15.37 | sector: PE 14.70 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.89x |
| Company: PE 15.37 | industry: PE 17.27 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 25.59 - 25.97 ( +/- 0.75%) |
| ATR Model: 14 days |
Forecast:
16:00 - $25.74
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $25.78 (-0.15% ) |
| Volume | 0.0010 mill |
| Avg. Vol. | 0.0058 mill |
| % of Avg. Vol | 17.21 % |
| Signal 1: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For FTXH
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
FTXH
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depository receipts that comprise the index. The index is designed to provide exposure to U.S. companies comprising the pharmaceutical sector that have been selected based upon their liquidity and weighted based upon their cumulative score on three investing factors: volatility, value and growth. It is non-diversified.
Last 10 Buy Signals
Latest News
2024-04-17 11:00:19 - Zacks Investment Research
JNJ Beats Q1 Earnings Estimates, Misses on Sales: ETFs in Focus
Johnson & Johnson (JNJ) continued with its long streak of earnings beat but lagged revenue estimates.
2024-02-12 14:01:05 - Zacks Investment Research
A Look at Pharma ETFs After Q4 Earnings
The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. However, many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
2023-11-08 12:46:40 - Zacks Investment Research
Pharma ETFs in Focus Post Q3 Earnings
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
2023-08-11 13:47:31 - Zacks Investment Research
Pharma ETFs in Focus Post Q2 Earnings
Second-quarter earnings beat ratio of 86.6% and revenue beat ratio of 84.9% for the healthcare sector are impressive.
2023-06-22 15:37:10 - Zacks Investment Research
Biotech ETFs in Focus on Covid Vaccines' Fall Rollout
The FDA advised to Pfizer, Moderna and Novavax to manufacture single-strain jabs targeting the omicron subvariant XBB.1.5 should prove to be a victory for some biotech ETFs.
2023-05-09 13:01:28 - Zacks Investment Research
Pharma ETFs Gain Post Q1 Earnings
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both. As such, pharma ETFs have been in the green over the past month.
2023-01-11 18:09:00 - Seeking Alpha
Can Health Care Stocks Outperform Again In 2023?
How a recession could impact health care stocks in 2023. As Covid continues, what it could mean for the health care sector.
2022-12-14 14:18:04 - Zacks Investment Research
5 Best Sector ETFs of 2022
Here are the top-performing sector ETFs of 2022. These include energy, healthcare, materials, utilities and consumer staples.
2022-12-13 12:48:18 - Zacks Investment Research
Amgen to Buy Horizon Therapeutics: ETFs to Bet On
Amgen (AMGN) has agreed to buy Horizon Therapeutics PLC (HZNP) for $27.8 billion. This put the spotlight on pharma ETFs, which could be the best way for investors to tap the opportunity arising from the proposed deal.
2022-12-06 14:18:05 - Zacks Investment Research
2 Sector ETFs Hovering Around a 52-Week High
We all know that Wall Street is shattered this year. Still, two sectors -- Biotech and Aerospace -- have recently hit a 52-week high.